OpenAI Funding
OpenAI Foundation: The Why and How of Its Life Science Research Funding Agenda
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-26-PA-12Oct 19, 2026
LAIs
Seven Biotechs Developing Long-Acting Injectable Drugs
Vedangi Joshi
Nice Insight
PAO-08-26-PA-10Aug 10, 2026
DBS
Advancing Deep Brain Stimulation Through Better Targeting and Smarter Devices
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-26-PA-23Jun 26, 2026
CNS Clinical
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969
Insilico Medicine
PR-06-26-01Jun 17, 2026
Protein Misfolding
Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-08Jun 15, 2026
Alzheimer Therapies
Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-05Jun 10, 2026
Neurology
Next-Generation Therapies for Neurological Diseases
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-04-26-PA-18Apr 24, 2026
Neuro RNA
Targeting RNA in the Nervous System: The Rise of Antisense and RNA Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-09Apr 15, 2026
Neuro Biomarkers
Precision Neurology: How Biomarkers Are Redefining Clinical Trial Design
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-08Apr 13, 2026
Neuro CMC
Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-03Apr 3, 2026
BBB
Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-02Apr 2, 2026
BBB
Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-01Apr 1, 2026
Dementia
Using Real-World Data to Close Treatment Gaps in Alzheimer’s Disease and Related Dementias
PointClickCare Life Sciences
PAO-12-25-CL-03Dec 11, 2025
Financing
Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform
Circular Genomics
PR-12-25-NI-01Dec 1, 2025
Mental Health
The Mental Health Gender Gap: Why Women Bear the Burden
Maggie Palmiero
Pharma's Almanac
PAO-08-25-NI-09Aug 15, 2025
Pediatric Cancer
Bridging the Gap in Pediatric Cancer Access...A Call to Investors and Pharma Leaders
Emilee Kudla; David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-25-NI-01Aug 1, 2025
Neurodegenerative
Leriglitazone Marketing Authorization Application Submitted For Treatment of Cerebral Adrenoleukodystrophy Has Been Validated
Minoryx
PR-07-25-NI-2Jul 23, 2025
Alzheimer's
Enhanced Genomics and The ALBORADA Drug Discovery Institute Partner to Accelerate Alzheimer's Drug Discovery
Enhanced Genomics
PR-06-25-NI-08Jun 24, 2025
Neuroscience
Designer Control: DREADDs and the Next Generation of Targeted Neuromodulation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-11May 29, 2025
Nanobodies
Therapeutic Nanobodies and Intrabodies Rewriting the Rules of Target Engagement
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-10May 27, 2025